Table 3.
Pharmaceutical therapy and ADR-related costs
| Products | Patients (N) | % of patients | Total pharmaceutical therapy costs per 28-day cycle |
| CDΚi | |||
| Palbociclib | 301 | 82.5 | 771 186.08 € |
| Ribociclib | 64 | 17.5 | 170 917.76 € |
| Combination therapies | |||
| Letrozole | 166 | 45.5 | 3 962.42 € |
| Fulvestrant | 196 | 53.7 | 48 231.68 € |
| Tamoxifen | 2 | 0.5 | 7.44 € |
| None | 1 | 0.3 | 0.00 € |
| Average pharmaceutical therapy cost per 28-day cycle per patient | 2 724.12 € | ||
| ADRs | N of grade 3–4 ADRs | ADR-related costs | |
| Neutropenia | 77 | 74 690.00 € | |
| Anaemia | 7 | 6 790.00 € | |
| Thrombocytopenia | 7 | 6 790.00 € | |
| Blood toxicity | 1 | 970.00 € | |
| Diarrhoea | 1 | 1 033.00 € | |
| Stomatitis | 1 | 231.00 € | |
| Total cost | 90 504.00 € | ||
ADR, adverse drug reaction; CDKi, cyclin-dependent kinase inhibitor; N, number.